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ABSTRACT
Myeloablative high-dose therapy and single autologous stem cell transplantation (HDT) is frequently
performed early in the course of multiple myeloma, supported by some randomized controlled trials
(RCTs) indicating overall survival (OS) and progression-free survival (PFS) benefit compared with non-
myeloablative standard-dose therapy (SDT). Other RCTs, however, suggest variable benefit. We therefore
undertook a systematic review and meta-analysis of all RCTs evaluating upfront HDT versus SDT in
myeloma. The primary objective was to quantify OS benefit with HDT, with PFS benefit a secondary
objective. Anticipating heterogeneity, sensitivity and subgroup analyses were undertaken to assess robust-
ness of results. Assessment of harms (treatment-related mortality) was also undertaken. We searched the
PubMed, Embase, and Cochrane Collection of Controlled Trials databases using the terms myeloma
combined with autologous or transplant or myeloablative or stem cell. In total, 3407 articles were accessed,
and 10 RCTs prospectively comparing upfront HDT with SDT, with >2-year follow-up, and reporting OS
benefit on an intent-to-treat basis were identified. Two reviewers independently extracted study charac-
teristics, interventions, and outcomes. Hazard ratios (with 95% confidence interval) were determined.
Nine studies comprising 2411 patients were fully analyzed. Significant heterogeneity was present. The
combined hazard of death with HDT was 0.92 (95% confidence interval, 0.74-1.13). The combined hazard
of progression with HDT was 0.75 (95% confidence interval, 0.59-0.96). The totality of the randomized
data indicates PFS benefit but not OS benefit for HDT with single autologous transplantation performed
early in multiple myeloma. Sensitivity and subgroup analyses supported the findings and indicated that,
contrary to current reimbursement criteria, PFS benefit with upfront HDT is not restricted to chemo-
responsive myeloma. However, the overall risk of developing treatment-related mortality with HDT was
increased significantly (odds ratio, 3.01; 95% confidence interval, 1.64-5.50). Hence, evaluating alternative
therapeutic options upfront may also be reasonable.
© 2007 American Society for Blood and Marrow Transplantation
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wNTRODUCTION
Upfront “high-dose” myeloablative therapy with
ingle autologous stem cell transplantation (HDT), typ-
cally performed after a few cycles of induction therapy,
s routinely recommended for most patients with newly piagnosedmultiple myeloma. Treatment withHDT and
ingle autologous transplantation is a category 1 recom-
endation of the National Comprehensive Cancer Net-
ork [1]; and since October 1, 2000, autologous trans-
lantation for multiple myeloma has been a covered
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J. Koreth et al.184rocedure in the United States, per criteria of the Cen-
ers for Medicare and Medicaid Services (CMS) [2].
yeloma is currently the leading indication for the
4500 autologous transplantations performed annually
n North America [3].
Various prospective randomized controlled trials
RCTs) [4,5], nonrandomized comparisons [6-8], and
ystematic reviews [9,10] have concluded that there is
verall survival (OS) and progression-free survival
PFS) beneﬁt to upfront HDT compared with non-
ransplantation options of “standard-dose therapy”
SDT) for de novo myeloma. However, other RCTs
ave indicated variable beneﬁt to upfront HDT in
yeloma [11,12]. Retrospective analyses are prone to
rrors of bias and confounding and may provide inac-
urate estimates of effect. Prospective randomization,
nalyzed on an intent-to-treat basis, is a powerful
eans of minimizing errors. Given data from addi-
ional RCTs, prior estimates of beneﬁt with upfront
DT need to be reassessed.
To arrive at comprehensive estimates of OS and
FS beneﬁt from the totality of the randomized data,
e undertook a systematic literature review and meta-
nalysis to identify all RCTs that address the utility of
pfront HDT versus SDT in myeloma.
ETHODS
ata Sources
We undertook 2 independent searches of the
edline (PubMed), Embase, and Cochrane Registry
f Controlled Trials databases using the search term
yeloma combined with autologous or transplant or my-
loablative or stem cell. Medline (PubMed) searches
ere restricted to RCTs in humans, in the English
anguage. Embase searches were restricted to articles
ith human subjects, in English. Cochrane database
earches were not restricted by language or to human
ubjects. Studies identiﬁed underwent title/abstract
eview, and clearly nonrelevant articles were dis-
arded. Text review of the remainder was performed
o assess their suitability. The bibliographies of re-
ained articles were examined to identify additional
tudies. A recent review and a meta-analysis of 3
CTs were also accessed to identify additional studies
hat met inclusion criteria [3,13].
tudy Selection
Studies included were prospective RCTs that eval-
ated upfront HDT for multiple myeloma, deﬁned
roadly as any myeloablative regimen with a single
utologous transplant (or equivalent, see below), ver-
us a comparator of upfront SDT, also deﬁned
roadly as any nontransplant option. Eligible RCTs
ad a minimum follow-up of 2 years and reported
azard ratios (HRs) for OS and/or PFS beneﬁt on an antent-to-treat basis (or provided data to estimate HR
95% conﬁdence interval [CI]) by the method of Par-
ar et al [14]. Unadjusted HR was used in the primary
nalysis of OS and PFS beneﬁt, and adjusted HR,
hen available, was used in a sensitivity analysis. Odds
atio (OR) was used for treatment-related mortality
TRM) assessment. When multiple publications re-
orted on the study, the most updated data were
nalyzed.
ata Extraction
Two reviewers abstracted the data independently
n a standardized format. The data collected for each
tudy included publication date, ﬁrst author, year of
nitial patient enrollment, number randomized to each
rm, patient age (years) at enrollment, duration of
ollow-up (months), number “at risk,” and number of
vents for death, progression, TRM in each arm, and
values for OS and PFS beneﬁt, if available. We also
ollected data on therapy: induction regimen and its
uration, mobilization regimen, source of stem cells
bone marrow [BM] or peripheral blood [PB]), HDT
nd SDT regimen and duration, and maintenance
herapy, if any. Discrepancies in data extraction were
esolved by consensus, referring back to the original
rticle, and contacting the study authors, if necessary.
The quality of the studies was assessed by number
f participating institutions (single or multiple),
ethod of randomization and allocation concealment
central assignment or not), dropout rate, crossover,
nd study power. Given the “hard” endpoints (OS and
FS) we did not assess the effect of blinding on out-
omes. We did not explicitly score the methodologic
uality of the included RCTs because the value of
oing so is controversial. Ad hoc scores may lack
emonstrated validity, and results may not be associ-
ted with quality [15-18]. Instead, we performed sub-
roup and sensitivity analyses and performed tests of
nteraction, as is widely recommended [17-19].
ata Synthesis
Data analysis was done using STATA 7 (STATA
orp, College Station, Tex). The Begg funnel plot
nd Egger test were used to investigate publication
ias [20,21]. Heterogeneity was assessed by a Q sta-
istic [22]. Meta-regression assessed the role of study
ize in heterogeneity. A Forrest plot with combined
R (95% CI) for OS and PFS beneﬁt of upfront
DT versus SDT was constructed using the random-
ffects model of DerSimonian and Laird [23]. A sim-
lar plot was constructed using OR (95% CI) for TRM
ssessment.
We explored heterogeneity and the robustness of
ur ﬁndings regarding OS and PFS beneﬁt by addi-
ional sensitivity and subgroup analyses. In sensitivity
nalyses of OS beneﬁt, we assessed the effect of using
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Upfront HDT versus SDT in Myeloma 185djusted HR, if reported by the individual studies. We
lso assessed the effect of including the omitted neg-
tive study (CIAM, see below) using a conservative
mputed HR. In additional sensitivity analyses of OS
nd PFS beneﬁt, we assessed the effect of omitting
onstandard studies and of individually removing each
CT from the analysis. In subgroup analyses, we
ssessed OS and PFS beneﬁt in 3 subgroups: studies
sing PB stem cells (PBSCs) as a source of stem cells,
tudies with longer-term follow up (48 months), and
tudies with lower crossover in the SDT arm.
This work was performed in accordance with the
uality of Reporting of Meta-analyses guidelines for
eta-analysis of RCTs [17].
ESULTS
ystematic Review
In total, 3407 articles were identiﬁed in the initial
igure 1. Search strategy ﬂow chart. The Embase, Pubmed, and
ochrane database search and the process of identifying relevant
andomized controlled trials (RCTs) for inclusion in the meta-
nalysis are shown. Note that the studies excluded on text review
ere often ineligible for multiple reasons; hence, the total number
f exclusions is larger than the number of studies excluded. *One
ublication, a meta-analysis of 3 RCTs, provided updated hazard
atio information on overall survival beneﬁt of high-dose therapy
nd single autologous stem cell transplantation (HDT) and was
sed in the analysis. SDT indicates nonmyeloablative standard-dose
herapy.nline database searches, delineated in Figure 1. After acreening titles/abstracts, 3249 clearly nonrelevant ar-
icles were excluded (eg, nonhuman studies, nonclini-
al studies, reviews, addressed unrelated questions).
he remaining 158 studies were retrieved. They were
eviewed independently in a structured format, and
tudies discarded if they were non-RCTs, did not
ompare upfront HDT with SDT, addressed other
uestions, or represented the same RCT. A recent
eview article and a meta-analysis of 3 RCTs were also
etrieved. The review article did not yield additional
elevant articles [3]. The meta-analysis provided up-
ated relative risk (HR) estimates for OS beneﬁt with
DT for 3 RCTs [13].
The search yielded 10 unique RCTs, detailed in
ables 1-3 [4,5,11,12,24-29]. Overall, the studies were
f good quality, being prospective randomized multi-
enter trials of adequate power, analyzed on an intent-
o-treat basis, performed at the national level in the
nited States and Europe, and published in well-
espected peer-reviewed journals (Table 2). They ini-
iated enrollment between 1990 and 2000. Study sizes
anged from 115 to 516 randomized patients. Patients
ad newly diagnosed multiple myeloma, primarily
urie-Salmon stage II or III (stage I was permitted in
ome studies), and were typically 65 years of age
M97G and PETHEMA enrolled patients 70 years
ld and IFM9906 enrolled patients 75 years old;
able 3). Measurements of myeloma burden at enroll-
ent were not consistently provided across studies.
nformation on treatment crossover, especially cross-
ver of SDT to HDT on disease progression, was
rovided for most studies. Two groups could be de-
ermined: a higher crossover group (including
AG90 and CIAM, trials speciﬁcally designed to
ompare upfront versus delayed HDT) with 42%-
8% SDT crossover, and a lower crossover group
ith 18%-23% crossover. SDT crossover information
as unavailable for 2 negative studies (HOVON,
FM9906).
A nonstandard study (CIAM) randomized patients
ith chemoresponsive myeloma to higher-dose induc-
ion therapy (vincristine/doxorubicin/dexamethasone
VAD] and melphalan 140 mg/m2 [MEL140]), to up-
ront HDT, versus no transplantation (salvage HDT
as allowed) [24]. Published in abstract form, it re-
orted no OS beneﬁt to upfront HDT in a format
recluding exact HR extraction. We imputed HR,
onservatively assuming P .1 (a bias favoring HDT),
or a later sensitivity analysis.
The remaining 9 studies, comprising data from
411 patients, evaluated various permutations of up-
ront HDT versus SDT for treatment of de novo
yeloma to assess the utility of early HDT. No 2
tudies had identical trial designs and therapeutic in-
erventions, understandable particularly given the
omplexity of HDT, which was typically undertaken
fter several cycles of multiagent induction chemo-
Table 1. Relevant Randomized Controlled Trials of Upfront HDT versus SDT for Myeloma*
Study ID Study Year n
Age
(y)
2-M
(mg/
L) DS III Follow-up (mo)
HDT Regimen
(Conditioning Regimen)
Stem Cell
Source SDT Regimen Conclusion
IFM90 Attal 1990 200 58 3.5 75% 37 SDT; 41 HDT (104-OS)† VMCP/BVAP¡ (Mel140/TBI-8) BM VMCP/BVAP OS: benefit;
EFS: benefit
MAG90 Fermand 1990 185 48 2.8 84% 58 (104-OS)† VAMP¡ (Cc/Cy/VP/Mel140/TBI-12) PBSC VMCP OS: no benefit;
EFS: benefit
MAG91 Fermand 1991 190 60 3.2 81% 120 VAMP¡ (Bu/Mel140 or Mel200) PBSC VMCP OS: no benefit;
EFS: benefit
CIAM Facon 1992 115 52 3.5 80% >24 (OS) VAD/Mel140¡ (Mel140/TBI-12) BM VAD/Mel140 OS: no benefit;
PFS: NR
MRC7 Child 1993 401 55 >4 NR 31.5 SDT; 40 HDT VAMPC¡ (Mel200 or Mel140/TBI) PBSC ABCM OS: benefit;
PFS: benefit
S9321 Barlogie 1993 516 55 3.5 57% 76 VAD¡ (Mel140/TBI-12) PBSC VAD-> VBMCP OS: no benefit;
PFS: no
benefit
PETHEMA Blade 1994 164 57 NR NR 56 VBMCP/VBAD¡ (Mel200 or Mel140/TBI-12) PBSC VBMCP/VBAD OS: no benefit;
PFS: no
benefit
HOVON Segeren 1995 261 55 3 77% 33 VAD¡ Mel70x2¡ (Cy60x4/TBI-9) PBSC VAD-> Mel70x2 OS: no benefit;
EFS: no
benefit
M97G Palumbo 1997 194 64 2.9 62% 39 SDT; 41 HDT VAD¡ (Mel100x2) PBSC MP OS: benefit;
EFS: benefit
IFM9906 Facon 2000 248 70? >3.5 NR 32 VAD¡ (Mel100x2) PBSC MPT OS: no benefit;
PFS: no
benefit
ABCM indicates doxorubicin, carmustine, cyclophosphamide, melphalan; 2M, -2 microglobulin; BM, bone marrow; Bu/Mel, busulphan, melphalan; BVAP, carmustine, vincristine, doxorubicin,
prednisone; Cc/Cy/VP/Mel140, lomustine, cyclophosphamide, etoposide, melphalan, XRT; Cy60, cyclophosphamide at 60 mg/kg; DS III, Durie-Salmon stage III; EFS, event-free survival; HDT,
high-dose therapy and single autologous stem cell transplantation; Mel70/100/140/200, melphalan at 70/100/140/200 mg/m2; MP, melphalan, prednisone; MPT, melphalan, prednisone, thalidomide;
NR, not reported; OS, overall survival; PBSC, peripheral blood stem cell; PFS, progression-free survival; SDT, nonmyeloablative standard-dose therapy; TBI-8/9/12, total body irradiation (XRT)
at 8/9/12 Gy; VAD, vincristine, doxorubicin, dexamethasone; VAMP, vincristine, doxorubicin, methylprednisolone; VAMPC, vincristine, doxorubicin, methylprednisolone, cyclophosphamide;
VBAD, vincristine, carmustine, doxorubicin, dexamethasone; VBMCP, vincristine, carmustine, melphalan, cyclophosphamide, prednisone; VMCP, vincristine, melphalan, cyclophosphamide,
prednisone.
*The study ID, ﬁrst author, year of initial patient enrollment, study size (n, number of patients randomized), median patient age (years) at enrollment, median 2M, percentage of patients with DS III
disease, and median duration of follow-up are listed. Information on HDT regimen, source of stem cells, SDT regimen, and conclusions regarding OS and PFS or EFS beneﬁt are also shown for
each study.
†Updated follow-up information (hazard ratio) on OS beneﬁt of HDT from a repeat publication.
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Table 2. Relevant Randomized Controlled Trials of Upfront HDT versus SDT for Myeloma: Study Quality*
Study ID Multicenter Randomization Assignment
Dropout after
Randomization
Salvage HDT
at Progression Power
IFM90 Yes Upfront Central 26% (HDT) 17% (HDT) 80% for 5-y OS of 10% (SDT) vs 50% (HDT)
Stratified: no 0% (SDT) 18% (SDT)
MAG90 Yes Upfront (after PBSC) Central 2% (HDT) NR (HDT) 80% for 20% decrease in OS rate (early vs late HDT)
Stratified: center 0% (SDT) 78% (SDT)†
MAG91 Yes Upfront Central 24% (HDT) 8% (HDT) 80% for survival benefit of HDT vs SDT, expected hazard ratio  0.6
Stratified: center 0% (SDT) 23% (SDT)
CIAM Yes? After VAD/Mel140: chemoresponsive only Central? 22% (HDT) NR (HDT) NR (“assessing survival benefit of early vs late HDT”)
Stratified: NR NR 42% (SDT)†
MRC7 Yes Upfront Central 25% (HDT) 2% (HDT) 80% for absolute 10% increased survival in HDT (target 710, actual 407)
Stratified: age/Cr/Hb/TBI 2% (SDT) 18% (SDT)
S9321 Yes After VAD: all Central 18% (HDT) NR (HDT) 81% for 33% improved survival in HDT vs SDT
Stratified: DS/2M/chemoresponse 17% (SDT) 55% (SDT)
PETHEMA Yes After VBMCP/VBAD: chemoresponsive
only
Central 10% (HDT) 14% (HDT) NR
Stratified: DS 7% (SDT) 18% (SDT)
HOVON Yes After VAD: all Central? 21% (HDT) NR (HDT) 80% for 15% better 2-y EFS after randomization in HDT (40% to 55%)
Stratified: center 36% (SDT) NR (SDT)
M97G Yes Upfront Central 22% (HDT) 30% (HDT) 90% for 20% increased 2-y EFS if 25% in SDT (target 240, actual 194)
Stratified: No 4% (SDT) 48% (SDT)
IFM9906 Yes Upfront Central NR (HDT) NR (HDT) NR
Stratified: center NR (SDT) NR (SDT)
2M indicates -2 microglobulin; Cr, creatine; DS, Durie-Salmon stage; EFS, event-free survival; Hb, hemoglobin; HDT, high-dose therapy and single autologous stem cell transplantation; Mel140,
melphalan at 140 mg/m2; NR, not reported; OS, overall survival; PPSC, peripheral blood stem cell; SDT, nonmyeloablative standard-dose therapy; TBI, total body irradiation; VAD, vincristine,
doxorubicin, dexamethasone; VBAD, vincristine, carmustine, doxorubicin, dexamethasone; VBMCP, vincristine, carmustine, melphalan, cyclophosphamide, prednisone.
*Further information on the 10 studies listed in Table 1 is provided to better describe study quality. Information on the trial design and randomization protocol is listed. Information on dropout after
randomization and crossover is provided and may be expected to reduce the differences between the 2 arms. Information on study statistical power calculations a priori is also provided. Areas of
uncertainty (?) are indicated.
†Per protocol, salvage HDT was undertaken upon disease progression.
Upfront
H
D
T
versus
SD
T
in
M
yelom
a
187
Table 3. Relevant Randomized Controlled Trials of Upfront HDT versus SDT for Myeloma: Entry Criteria, Toxicity, Response, and Maintenance Therapy*
Study ID Entry Criteria
TRM CR Maintenance
SDT HDT SDT HDT SDT HDT
IFM90 Untreated MM DS II/III; age <65 y; LVEF/DLCO >50%; adequate hepatic
function; no other cancer or psychiatric disease
5.0% 7.0% 5%†† 22%†† IFN IFN
MAG90 Untreated symptomatic MM DS II/III (1 course of steroids and/or local
XRT not precluding TBI was allowed); age <56 y; adequate cardiac,
pulmonary, hepatic, and renal functions
0%† 12.1† 5% 19% IFN IFN
MAG91 Untreated symptomatic MM DS II/III (1 course of steroids and/or local
XRT not precluding TBI was allowed); age 55-65 y; adequate cardiac,
pulmonary, hepatic, and renal functions
2.1%‡ 5.3%‡ 4% 6% IFN IFN
CIAM Untreated MM DS II/III; age <60 y 1.8% 5.0% 18% 32% IFN IFN
MRC7 Untreated MM; met MRC criteria for treatment; age <65 y; suitable
candidate for HDT
NR¶ 3.0%§ 8% 44% IFN IFN
S9321 Untreated symptomatic MM; age <70 y; PS 0-2#; LVEF/DLCO >50%; no
prior malignancy (except nonmelanoma skin tumor or cervical
carcinoma in situ) in past 5 y
0.4% 3.4% 11% 11% IFN vs none§§ IFN vs none§§
PETHEMA Newly diagnosed untreated symptomatic MM DS II/III; age <65 y‡‡; PS 0-2 3.6% 3.7% 11% 30% IFNDex IFNDex
HOVON Untreated MM DS II/III A/B; PS <4**; adequate pulmonary, cardiac,
neurologic, metabolic, and hepatic functions; no prior extensive XRT or
malignant disease (except nonmelanoma skin tumor or stage 0 cervical
carcinoma)
1.3% 5.2% 13% 29% IFN IFN
M97G Untreated MM; age 50-70 y; LVEF/DLCO >50%; adequate hepatic, renal
function; no hepatitis B or C or HIV; no cancer or psychiatric disease
0% 2.1% 6%†† 25%†† IFNDex IFNDex
IFM9906 MM; age 65-75 y 0% 4.0% 16% 17% — —
CR indicates complete remission; DLCO, diffusing capacity of the lung for carbon monoxide; HDT, high-dose therapy and single autologous stem cell transplantation; HIV, human immunodeﬁciency
virus; IFN, interferon; IFNDex, interferon plus dexamethasone; LVEF, left ventricular ejection fraction; MM, multiple myeloma; nCR, near complete remission; NR, not reported; PS, performance
status score; SDT, nonmyeloablative standard-dose therapy; TBI, total body irradiation; TRM, transplant-related mortality; XRT, radiation therapy.
*Additional information on the trial entry criteria, TRM and CR rates, and maintenance therapy on the 10 studies listed in Table 1 is provided, when available from the original publications. The TRM
data in particular were variably reported and had to be inferred for some studies, as indicated.
†TRM at 1 year; in the SDT arm, TRM after salvage HDT was 14%.
‡TRM at 6 months; in the HDT arm, 1 of 71 patients who actually underwent stem cell transplantation had a toxic death.
§TRM at 100 days after stem cell transplantation.
TRM within 3 months after myeloablative therapy was 3.9%.
¶Imputed as 0 for calculating odds ratio.
#Zubrod PS; PS 3-4 as a result of myeloma related bone disease was permitted.
**World Health Organization PS.
††Including nCR. In IFM90, CR was not conﬁrmed by immunoﬁxation in all cases. CR was not a category for M97G (only nCR used).
‡‡From 1997 the upper age limit was extended to 70 years.
§§Chemoresponders were randomized to IFN versus observation.
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Upfront HDT versus SDT in Myeloma 189herapy. HDT comprised autologous stem cell collec-
ion from PB or BM (with or without growth factors
nd/or chemotherapy) followed by myeloablative con-
itioning chemotherapy (with or without radiation)
nd subsequent autologous stem cell infusion (with or
ithout growth factor support). The patients were
andomized upfront or after induction therapy. Sev-
ral RCTs used additional nonstandard approaches, as
iscussed below. These were included in the initial
nalysis and removed in a sensitivity analysis.
In a nonstandard study evaluating patients 50-70
ears of age (M97G), the HDT arm received mul-
iagent induction therapy (VAD) followed by tandem
utologous transplants, each after “intermediate-dose”
elphalan conditioning (MEL100) [27]. The total
onditioning dose (MEL100x2) was considered possi-
ly similar to that used for single autologous trans-
lantation (MEL200); hence, the study was included
n the initial analysis. Tandem transplantation in the
DT arm, lower intensity chemotherapy (melphalan-
rednisone) for the SDT arm, and lack of equivalent
nduction therapy in the SDT arm were nonstandard.
A similar nonstandard study (IFM9906), a recent
lenary presentation at the 2006 annual meeting of
he American Society of Clinical Oncology, evaluated
atients 65-75 years of age by comparing HDT com-
rising multiagent induction therapy (VAD) followed
y tandem autologous transplants, each after interme-
iate-dose MEL100 conditioning, with SDT com-
rising melphalan/prednisone/thalidomide chemo-
herapy only [29]. Considering the total conditioning
ose (MEL100x2) as possibly comparable to the
EL200 used in other studies, this study was included
n the initial analysis. The elderly study population,
andem intermediate-dose transplants in the HDT
rm, and lack of equivalent induction therapy in the
DT arm were nonstandard.
Another nonstandard study (HOVON) used more
ntensive induction chemotherapy (VAD plus
EL70x2) for all, adding myeloablative conditioning
cyclophosphamide) and autologous transplantation in
he HDT arm [26]. The higher doses of chemother-
py, occasionally necessitating stem cell rescue in the
DT arm, were considered nonstandard.
In the fourth study (MAG90), subjects in the SDT
rm were permitted salvage HDT, per protocol, for
isease relapse or progression, a nonstandard ap-
roach [25]. This study design was acceptable for
nclusion in the initial analysis because a proportion of
atients randomized to the SDT arm in other studies
lso went on to receive rescue HDT upon disease
rogression.
A ﬁfth study (PETHEMA) provided upfront in-
uction therapy (VAD), randomizing only chemore-
ponsive patients to HDT versus SDT, arguably a
onstandard approach [11]. This was acceptable for
nclusion in the initial analysis because most patients nn the other studies had chemoresponsive disease, in-
icating substantial overlap in patient populations.
ublication Bias
We constructed funnel plots to evaluate for pub-
ication bias. The Begg funnel plot for OS beneﬁt had
relatively symmetric distribution, arguing against
ublication bias (Begg test, P  .92; Egger test, P 
91). Similarly, the funnel plot for PFS beneﬁt showed
o evidence for publication bias visually or statistically
Begg test, P  .47; Egger test, P  .95).
DT and OS Benefit
All studies reported OS as the primary endpoint.
he summary hazard estimates vary between studies,
anging from 0.40 (HDT better) to 1.70 (SDT better).
here was signiﬁcant heterogeneity in the estimates
cross studies, with a Q statistic of 27.65 (P  0.01; 8
f). Meta-regression indicated no role for study size in
eterogeneity (P  .87).
A Forrest plot of the individual and combined
Rs (95% CI) for OS beneﬁt with upfront HDT is
hown in Figure 2. The combined HR for OS beneﬁt
as 0.92 (95% CI, 0.74-1.13) for the 9 studies. The
verall estimate does not indicate a statistically signif-
cant reduction in hazard of death with upfront HDT
or newly diagnosed myeloma (P  .40).
We explored the robustness of the results with
ensitivity analyses, summarized in Figure 2. Using
djusted HR, when available, for OS beneﬁt indicated
combined HR of 0.92 (95% CI, 0.75-1.13). For the
egative CIAM study, a conservative bias in favor of
DT yielded an unlikely study HR of 0.51 (95% CI,
.23-1.14), given the known study OR of 0.90 (95%
I, 0.36-2.20), yet resulted in an overall HR of 0.89
95% CI, 0.73-1.09) for all 10 studies. Of the original
RCTs, upon removing the 2 nonstandard tandem
ntermediate-dose studies (M97G, IFM9906), com-
ined HR for OS beneﬁt for the remaining 7 studies
as 0.91 (95% CI, 0.80-1.04). Similarly, upon exclud-
ng all nonstandard studies (M97G, HOVON,
AG90, PETHEMA, IFM9906), combined HR of
S beneﬁt for the remaining 4 studies was 0.85 (95%
I, 0.71-1.03). Removing any single study from the
nalysis did not reduce the combined 95% CI below
.00 (data not shown).
In a subgroup analysis, OS beneﬁt for the 8 studies
referentially using PBSCs as a stem cell source indi-
ated a combined HR of 0.95 (95% CI, 0.76-1.19).
imilarly, OS beneﬁt for the 5 studies with longer
ollow-up (48 months) yielded a combined HR of
.92 (95% CI, 0.80-1.06). OS beneﬁt for studies with
ower crossover in the SDT arm indicated a combined
R of 0.83 (95% CI, 0.69-1.01), despite excluding 2
egative studies with missing crossover information
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J. Koreth et al.190HOVON, IFM9906). Tests of interaction for sec-
ndary analyses were nonsigniﬁcant.
DT and PFS
No estimate of PFS beneﬁt was available for the
IAM study. The remaining 9 studies reported on
yeloma-free survival. This outcome was deﬁned
ariably as event-free survival or PFS. Both terms have
een grouped together as PFS for this analysis because
hey are similarly deﬁned as time from randomization
o death, progression, or relapse, censored at last
nown follow-up. HR for PFS beneﬁt ranged from
.42 (HDT better) to 1.80 (SDT better). Signiﬁcant
eterogeneity was present between studies, with a Q
tatistic of 51.57 (P  .01; 8 df). Meta-regression did
ot detect a signiﬁcant role for study size in hetero-
eneity (P  .56).
igure 2. Forrest plot of overall survival (OS) beneﬁt of upfront hig
yeloma. The individual randomized controlled trials (RCTs) are
or individual RCTs are indicated by black rectangles (the size of the
5% conﬁdence intervals (CIs). The overall summary effect estimate
fter sensitivity and subgroup analyses are shown below. The corre
tudy. ‡ Two negative studies (HOVON, IFM9906) with missing
eripheral blood stem cell; SDT, nonmyeloablative standard-doseThe Forrest plot with individual and combined sRs (95% CI) for PFS beneﬁt with HDT is shown in
igure 3. The combined HR for the 9 studies was 0.75
95% CI, 0.59-0.96), indicating statistically signiﬁcant
FS beneﬁt with upfront HDT (P  .02). We ex-
lored the robustness of the result with sensitivity
nalyses, summarized in Figure 3. Removal of the 2
andem intermediate-dose studies (M97G, IFM9906)
ndicated a combined HR for PFS beneﬁt of 0.71
95% CI, 0.59-0.85) for the remaining 7 studies. Fur-
her, removal of all nonstandard studies (MAG90,
97G, HOVON, PETHEMA, IFM9906) yielded a
FS beneﬁt combined HR of 0.75 (95% CI, 0.65-
.87) for the 4 remaining studies. Individually remov-
ng any study from the combined analysis did not
iden the 95% CI above 1.00 (data not shown).
On subgroup analysis (Figure 3), the PFS beneﬁt
n 8 studies using PBSCs preferentially as a stem cell
therapy and single autologous stem cell transplantation (HDT) in
ed on the y axis. The summary effect estimate (hazard ratio [HR])
gle is proportional to the study weight), with the lines representing
and 95% CI are indicated by the diamond below. Overall estimates
ng values for HR (95% CI) are indicated alongside. *Nonstandard
ver information were omitted from this analysis. PBSC indicates
.h-dose
indicat
rectan
(HR)
spondi
crossoource yielded a combined HR estimate of 0.77 (95%
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Upfront HDT versus SDT in Myeloma 191I, 0.59-1.00). The 4 studies with longer follow-up
48 months) had a combined HR estimate of 0.70
95% CI, 0.51-0.96). After omitting 2 negative studies
HOVON, IFM9906) with missing crossover infor-
ation, the 4 studies with lower SDT crossover had a
ombined HR estimate of 0.72 (95% CI, 0.62-0.83).
ests of interaction for secondary analyses were non-
igniﬁcant.
DT and TRM
Information on toxic deaths was reported directly
r indirectly (eg, as percentage) for most studies (Ta-
le 3). However, information on the denominator
number at risk) was variably reported, if at all. Hence,
n the interests of uniformity, all patients enrolled on
n intention-to-treat basis were included in the de-
ominator across studies. Because this may underes-
igure 3. Forrest plot of progression-free survival (PFS) beneﬁt of
HDT) in myeloma. The individual randomized controlled trials (
ation [HR]) for individual RCTs are indicated by black rectangles
epresenting 95% conﬁdence intervals (CIs). The overall summary
stimates after additional sensitivity and subgroup analyses are sh
longside. * Nonstandard study. ‡ Two negative studies (HOVON
nalysis. PBSC indicates peripheral blood stem cell; SDT, nonmyeimate the actual toxicity of undergoing therapy, it is a qias favoring the more toxic treatment (HDT). The
orrest plot with individual and combined OR for
RM risk with HDT is shown in Figure 4. The
ombined OR for the 9 studies was 3.01 (95% CI,
.64-5.50), indicating signiﬁcantly increased TRM
ith upfront HDT (P  .01).
ISCUSSION
Early autologous transplantation for myeloma is
ommon, based on observational and RCT data indi-
ating signiﬁcant OS beneﬁt for HDT performed
fter a few cycles of multiagent induction chemother-
py. Child et al [5], presenting their study ﬁndings,
ombined OR estimates from 3 RCTs to demonstrate
tatistically signiﬁcant OS beneﬁt to upfront HDT.
ubsequently, RCTs addressing the same overall
high-dose therapy and single autologous stem cell transplantation
are indicated on the y axis. The summary effect estimate (hazard
ze of the rectangle is proportional to the study weight), with lines
estimate (HR) and 95% CI are indicated by the diamond. Overall
elow. The corresponding values for HR (95% CI) are indicated
9906) with missing crossover information were omitted from this
ive standard-dose therapy.upfront
RCTs)
(the si
effect
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J. Koreth et al.192ient eligibility, population randomized, speciﬁcs of
DT and SDT, and other study factors, have reached
ifferent conclusions regarding the utility of such up-
ront HDT. However, the effect, if any, of this addi-
ional information is unclear, and treatment of my-
loma remains the leading indication for autologous
ransplantation in North America.
In part this may be because all the RCT data
ave not yet been systematically assessed. In this
egard, heterogeneity arising from structural and
ethodologic differences between studies may be a
actor, despite their similar overall focus on evalu-
ting the utility of upfront HDT versus nontrans-
lantation therapeutic options in myeloma. How-
ver, failing to systematically assess the available
ata is suboptimal, resulting in a relatively arbitrary
referment of individual study results or an “intui-
ive” data synthesis, without objective means to test
he robustness of any conclusions. Instead, quanti-
atively integrating the total RCT data available will
igure 4. Forrest plot of treatment-related mortality risk of upfront
n myeloma. The individual randomized controlled trials (RCTs) a
ndividual RCTs are indicated by black rectangles (the size of the re
onﬁdence intervals (CIs). The overall summary effect estimate (
onmyeloablative standard-dose therapy.ikely enhance our understanding of the role of bDT in newly diagnosed myeloma. The robustness
f any conclusions can then be systematically as-
essed in secondary analyses.
It is possible that the favorable early RCT results
ere simply the play of chance. For instance, the ﬁrst
rial comparing HDT with SDT reported an absolute
S beneﬁt of 40%, an improvement rarely sustained
n oncology [4]. A subgroup comparison of the 3
CTs reported by Child et al [5] with the subsequent
rials yielded a nonsigniﬁcant test of interaction (data
ot shown) and supports our evaluating the RCT data
n its entirety. Promising early results can lead to
optimism bias” with subsequent rapid adoption of
ew technologies [30].
To comprehensively assess the utility of early my-
loablative therapy with single autologous transplan-
ation in myeloma, we deﬁned HDT and SDT
roadly to identify all relevant RCTs evaluating up-
ront transplant versus nontransplant modalities and
sed the random effects model to quantify overall
ose therapy and single autologous stem cell transplantation (HDT)
cated on the y axis. The summary effect estimate (odds ratio) for
e is proportional to the study weight), with lines representing 95%
atio) and 95% CI are indicated by the diamond. SDT indicateshigh-d
re indi
ctangl
odds reneﬁt. We also identiﬁed nonstandard studies a pri-
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Upfront HDT versus SDT in Myeloma 193ri (to guard against “cherry picking”) and assessed
heir effect on the results.
The systematic literature search identiﬁed 10
rospective RCTs comparing upfront HDT with
DT for newly diagnosed multiple myeloma, 3 of
hich (IFM90, MRC7, and M97G) reported OS
eneﬁt to upfront HDT (Table 1). Initiated be-
ween 1990 and 2000, the studies are relatively
ature. They varied in the speciﬁc therapies used
Table 1). For the HDT arm, myeloablative condi-
ioning commonly comprised 200 mg/m2 melphalan
MEL200) or 140 mg/m2 melphalan plus 8- to
2-Gy total body irradiation (TBI). PBSCs were the
referred stem cell source in all except 2 studies
IFM90, CIAM). One negative study (CIAM) pro-
ided limited information on OS beneﬁt and could
ot be included in the initial analysis (but was used
n a sensitivity analysis). Nine studies were system-
tically assessed to obtain a combined HR (95% CI)
or OS and PFS beneﬁt. Five of these studies
MAG-90, M97G, HOVON, PETHEMA, and
FM9906) were considered nonstandard. They were
ncluded in the initial analysis and removed in a
ensitivity analysis.
As anticipated, despite their similar overall focus
n the utility of upfront HDT for myeloma, structural
ifferences between studies likely resulted in the sig-
iﬁcant heterogeneity observed across studies. Differ-
nces in study size, duration of follow-up, or stem cell
ource did not explain the heterogeneity observed.
ecause we depended on data extractable from the
riginal publications, we could not assess the role of
ther patient or disease variables (eg, performance
tatus, serum creatinine, -2 microglobulin, disease
tage, cytogenetics) in explaining heterogeneity.
Our primary ﬁnding is that the totality of the
andomized data indicate no statistically signiﬁcant
S beneﬁt to upfront HDT in newly diagnosed my-
loma (P  .40). The lack of OS beneﬁt was evident
espite our inability to include a relevant negative
tudy (CIAM). This conclusion was supported by var-
ous sensitivity and subgroup analyses. The ﬁnding
as not dependent on an individual study because
emoval of any single study did not change the con-
lusion. Similarly, excluding nonstandard studies did
ot affect the overall conclusion. Lack of longer-term
ollow-up is also unlikely to explain the negative ﬁnd-
ngs because the studies are relatively mature, being
nitiated in the previous decade. Further, the studies
eporting signiﬁcant OS beneﬁt did not have appre-
iably longer follow-up than the negative studies, and
he subgroup of studies with longer follow-up (48
onths) also showed no OS beneﬁt. A secondary
nding is of statistically signiﬁcant PFS beneﬁt with
pfront HDT (P  .02). The PFS beneﬁt was stable
n sensitivity and subgroup analyses.Would improved HDT methodologies result in [mproved OS beneﬁt? Owing to faster engraftment
nd lower anticipated toxicity, PBSCs are preferred to
M as a stem cell source for autologous transplanta-
ion [10]. Interestingly, overall results from the 8
CTs preferentially using PBSCs did not indicate
reater OS beneﬁt. Similarly, for HDT, myeloablative
onditioning with MEL200 is considered less toxic
nd preferable to MEL140/TBI [31]. Most studies
nalyzed permitted MEL200 or MEL140/TBI condi-
ioning in the HDT arm and did not report outcomes
eparately on this basis. We therefore cannot com-
ent on the effect of MEL200 conditioning directly,
ut have listed the TRM for each study, if available, in
able 3. In addition, maintenance therapy, typically
ith interferon, was typically used for the HDT and
DT arms in these studies. However, the single study
ddressing the role of maintenance therapy (S9321)
andomized responsive patients in both arms to inter-
eron versus observation and found no OS or PFS
eneﬁt with maintenance interferon.
There does not appear to be any simple concor-
ance between these methodologic factors and out-
ome. For instance, the IFM90 study, despite using
EL140/TBI conditioning and BM stem cells in the
DT arm, reported highly signiﬁcant OS beneﬁt for
pfront HDT. It is therefore less likely that lack of
BSCs or MEL200 in the HDT arm signiﬁcantly
ccounts for the lack of overall OS beneﬁt. Interest-
ngly, dexamethasone, a highly active agent in my-
loma, was not used in 2 of the studies indicating OS
eneﬁt to upfront HDT (IFM90, MRC7). It is a
atter of speculation as to whether using more active
gents for induction or maintenance would have im-
roved outcomes in the SDT arms.
What about the role of treatment crossover? A
igniﬁcant fraction of patients randomized to SDT
ltimately received salvage HDT on or off protocol
Table 2). The 2 studies (MAG90, CIAM) directly
valuating “early” (upfront) HDT versus “delayed”
DT (no upfront transplantation, with provision for
escue HDT, ie, crossover) independently concluded
hat there was no OS beneﬁt to upfront HDT. Such
rossover, analyzed on an intent-to-treat basis, is an-
icipated to reduce observable differences in outcome.
mportantly however, crossover of patients on the
DT arm occurred primarily upon disease progres-
ion or relapse, and a priori, salvage HDT performed
ater in the disease course was not anticipated to be
quivalent to upfront HDT. In addition, studies in the
ower crossover group showed no overall OS beneﬁt
o upfront HDT, despite excluding 2 negative studies
HOVON, IFM9906) lacking crossover information.
What is the role of early HDT in chemorespon-
ive myeloma? CMS criteria speciﬁcally mandate che-
oresponsive disease (with at least a partial response
o induction therapy) to be eligible for upfront HDT
2]. However, the 2 RCTs evaluating HDT in this
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J. Koreth et al.194etting (CIAM, PETHEMA) concluded there was no
S beneﬁt. The randomized OS data therefore do not
upport the CMS requirement. However, chemother-
py responsiveness was deﬁned broadly in studies,
hereas it may be reasonable to consider the minority
f patients with a complete response distinct from
hose with a partial response. Nevertheless, eviden-
iary basis for this reimbursement criterion is unclear.
iven its emphasis on linking evidence-based decision
aking to reimbursement, our analysis has immediate
ractical implications for CMS: approval criteria for
utologous transplantation in myeloma should be re-
ised to remove this restriction. If transplantation is
onsidered beneﬁcial for patients with chemorespon-
ive disease on the basis of PFS beneﬁt, it is equiva-
ently so for all patients with newly diagnosed my-
loma.
We caution that a ﬁnding of a lack of signiﬁcant
S beneﬁt with upfront HDT cannot be interpreted
s arguing against any role for autologous transplan-
ation in myeloma. A signiﬁcant PFS beneﬁt alone
ay constitute sufﬁcient justiﬁcation for upfront
DT, particularly if a quality-of-life beneﬁt can be
emonstrated. It is also possible that certain patient
ubgroups (eg, poor-risk cytogenetics) may obtain
eneﬁt signiﬁcantly different from the overall esti-
ates we derived. However, it is also important to
onsider the harms associated with upfront HDT,
articularly given the documented lack of OS beneﬁt.
ur TRM analysis indicates that the overall odds of
eath due to treatment toxicity are signiﬁcantly in-
reased with upfront HDT (OR, 3.01; 95% CI, 1.64-
.05). Given an event rate of 2.0 % in the SDT arm
weighted SDT average across studies), 1 excess toxic
eath per 26 patients enrolled may be anticipated
ith upfront HDT compared with SDT (Table 4).
he dilemma with upfront HDT is thus between
ncreased short-term risks (TRM) and long-term PFS
eneﬁt.
There are limitations to our analysis. As a meta-
nalysis of the published literature, we extracted sum-
ary risk statistics (HR) from individual studies to
etermine combined risk estimates. Dependence on
ublished articles limit the level of detail that can be
aptured regarding subgroups that may have greater
r lesser beneﬁt from the intervention, an area of
articular interest. A meta-analysis of updated individ-
al patient data from all 10 RCTs is an optimal way to
etermine more complete estimates of OS and PFS
eneﬁt with HDT and to assess additional outcomes
uch as effect on quality of life (eg, TWiST, Time
ithout Symptoms or Toxicity). The proposed meta-
nalysis could also assess additional patient, disease, or
reatment covariates that affect outcomes of interest
eg, cytogenetics). Nonetheless, our quantitative anal-
sis of published data from 9 RCTs comprising 2411
rospectively randomized patients provides the most complete estimate of treatment effect available. It
orms the basis for an informed assessment of the
eneﬁts of upfront HDT in newly diagnosed multiple
yeloma.
If upfront HDT using single autologous trans-
lantation does not offer a signiﬁcant OS beneﬁt, how
hould we treat newly diagnosed myeloma? A priori, 2
lternative approaches appear attractive. One ap-
roach, using more intensive therapy with upfront
andem autologous stem cell transplantation (HDT 
), has randomized data supporting its use, and addi-
ional studies are underway [32,33]. Similarly, evalu-
tion of intensive therapy with nonmyeloablative al-
ogeneic transplantation is ongoing [34,35].
Conversely, newer myeloma-speciﬁc therapies
eg, thalidomide, bortezomib, lenalidomide) offering
nhanced response rates are available [36-38]. In this
egard, it is interesting that the IFM9906 study, show-
ng OS and PFS beneﬁts to SDT, added thalidomide
o the standard melphalan-prednisone chemotherapy
rm. Increasingly used for induction therapy before
ransplantation and for maintenance therapy after
ransplantation, such agents may also improve the
fﬁcacy of HDT. It will be important to prospectively
valuate the beneﬁt of early versus delayed HDT in
he context of such novel agents, to better deﬁne their
ole in the treatment of de novo myeloma.
Choosing between these different options is not
traightforward. Many would consider a PFS beneﬁt
ufﬁcient basis for upfront HDT in patients with
ewly diagnosed myeloma. Whether this argument is
ersuasive given the availability of newer antimyeloma
herapies and whether beneﬁt is equivalent for all
able 4. Assessment of Potential Harm (TRM) with Upfront HDT*
TRM Event Rate Number Needed for
Treatment Harm
(HDT)†
Number of Excess
Events (Toxic
Deaths)/1000†
DT
roup
HDT
Group†
.005 0.015 101.0 9.9
.010 0.030 51.3 19.5
.015 0.044 34.7 28.8
.020 0.058 26.4 37.9
.025 0.072 21.4 46.6
.030 0.085 18.1 55.2
DT indicates high-dose therapy and single autologous stem cell
transplantation; SDT, nonmyeloablative standard-dose therapy;
TRM, transplant-related mortality.
Table presents the anticipated TRM with upfront HDT (based on
3-fold increased odds of death with HDT versus SDT), for a
range of possible TRM rates in the SDT arm. Based on these
estimates, the number of patients that need to be enrolled to the
HDT arm to have 1 excess HDT toxicity-related death (versus
those in the SDT arm) is also indicated, as is the number of such
excess deaths anticipated per 1000 patients enrolled to upfront
HDT.
Based on an odds ratio of 3.010 applied to the control group
(SDT) event rate.linically relevant subgroups is unclear. Decisions re-
g
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Upfront HDT versus SDT in Myeloma 195arding the role and timing of HDT will need to be
ade in collaboration with our patients, acknowledg-
ng uncertainty, and incorporating their preferences.
nrollment in clinical trials that seek to address such
ssues is to be encouraged.
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